12 results about "SECRETOR FACTOR" patented technology

Provided herein are epicardium-derived paracrine factors for repairing heart tissue. In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors, such as hypoglycosylated follicular- stimulating hormone-like 1 (FSTL1), for treating and repairing damage to heart tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or heart growth defects, and methods of using the same.

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

Described herein are methods and culture medium, useful for inducing polarization in multipotent stem cells. Additionally, described herein are multipotent cells produced by the methods and culture medium of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells that are produced by the methods and culture medium of this disclosure that are useful as therapeutic agents.

Provided is a technique for producing an organoid that is larger in size and more functionally excellent than conventional organoids. The present invention employs a method for producing an organoid, the method comprising: a step (A1) for culturing an organoid, in which an organoid produced from undifferentiated cells, mesenchymal cells, and vascular cells that differentiate into a first organ is brought into a secretion factor secreted from a second organ; and a step (A2) for culturing the organoid cultured in the step (A1). In the step (A1) and the step (A2), the dissolved oxygen partial pressure of a medium in contact with the organoid is 20% or less. The dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A1) is lower than the dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A2).

Described herein are methods and culture medium, useful for inducing polarization in multipotent stem cells. Additionally, described herein are multipotent cells produced by the methods and culture medium of this disclosure that are useful therapeutic agents. Also described herein are extracellular vesicles and factors secreted by multipotent cells that are produced by the methods and culture medium of this disclosure that are useful as therapeutic agents.

This invention relates to an in vitro maturation culture medium for giant panda oocytes and its application, belonging to the field of biotechnology. The invention discloses an in vitro maturation culture medium for giant panda oocytes, which simultaneously adds the following three paracrine factors to the basal culture medium: adenosine diphosphate riboylation factor 6 (ARF6); ciliary neurotrophic factor (CNTF); and hepatocyte growth factor (HGF). The invention also provides the application of the aforementioned in vitro maturation culture medium for giant panda oocytes, specifically for the in vitro maturation culture of giant panda oocytes. This invention effectively addresses the shortcomings of existing in vitro oocyte maturation technologies, significantly improves oocyte maturation quality, is simple to operate, and has high safety, providing a key technological reserve for assisted reproduction in giant pandas.

Provided is a prophylactic and / or therapeutic agent for photodermatitis caused by light exposure. This prophylactic and / or therapeutic agent for a skin disorder caused by light exposure contains an inhibitor for cellular senescence-associated secretory phenotype factors (SASP factors) as an active ingredient. As a result of exploring responses to light exposure in melanocytes and comprehensively analyzing molecules that can be therapeutic target seeds related to the skin disorder, it was shown that cellular senescence occurs in melanocytes after light exposure. In melanocytes having undergone cellular senescence, enhanced expression of an SASP factor group was observed, and this led to the finding that an inhibitor for SASP factors is effective for preventing and / or treating the skin disorder.

The application discloses a research method for tumor cell influence mechanism of monocyte remodeling based on bone marrow inflammatory microenvironment, and relates to the technical field of tumor treatment; and comprises the following steps: S1, providing bone marrow plasma from a classic myeloproliferative neoplasm patient; S2, placing primary CD14+ monocytes from a healthy donor in an in-vitro culture system containing the bone marrow plasma, inducing phenotype remodeling of the monocytes, and obtaining the remodeling monocytes. The application establishes CD163+CD206+ double-positive remodeling monocytes as a new target for MPN treatment; through comparison experiments of direct co-culture and indirect co-culture by Transwell, it is confirmed that the promotion effect of the remodeling monocytes on HEL cell proliferation strictly depends on physical contact between cells, rather than soluble secreted factors; and the application provides a theoretical basis for developing new antibody drugs or small molecule inhibitors for blocking cell-cell interaction.

The application relates to the technical field of cell biology, and particularly relates to application of a skin organoid conditioned medium in promoting repair of acute skin damage tissue, to a human skin organoid in-vitro model, to collection of a skin organoid conditioned medium (SOCCM) cultured for 6-8 days, enrichment of a variety of secretory factors related to skin repair, inflammation control and angiogenesis in the skin organoid conditioned medium, formation of a characteristic secretome, in-vivo and in-vitro experiment verification that the skin organoid conditioned medium can significantly promote fibroblast migration, vascular endothelial cell lumen formation, accelerate acute skin damage wound closure, promote collagen ordered deposition and tissue remodeling, and improve skin damage repair quality. The application avoids tumorigenic and immunological rejection risks of the organoid / stem cell transplantation, provides a new treatment strategy for repair of the acute skin damage, and can also be applied to repair of chronic non-healing wounds and repair of skin light damage and the like.

The application belongs to the technical field of genetic engineering and cell modification, and discloses a construction method and application of anti-fibrosis mesenchymal stem cells. The application finds and verifies the key role of AHNAK gene in the regulation of MSC anti-fibrosis function, and AHNAK knockdown can significantly improve the survival rate of MSC under hypoxic conditions. The application innovatively associates AHNAK with the fibrosis microenvironment adaptation ability of MSC, providing a new target for MSC function modification. The AF-MSC constructed by the application can inhibit the transformation of fibroblasts into myofibroblasts, increase the secretion of anti-fibrosis paracrine factors, significantly reduce collagen deposition, significantly enhance the anti-fibrosis effect, improve the treatment efficiency of single administration, reduce the need for repeated administration, and reduce the overall treatment cost.

Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.